FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Rhea-AI Summary

FibroBiologics (Nasdaq:FBLG) announced that its Founder and CEO Pete O'Heeron and CSO Hamid Khoja, Ph.D., will join a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference, held June 30–July 1, 2026.

The session is scheduled for 1:00 p.m. ET on June 30, 2026 and will be moderated by Matthew Caufield, Senior Research Healthcare Analyst at H.C. Wainwright & Co. FibroBiologics will also be available for one-on-one investor meetings during the event.

News Market Reaction – FBLG

+19.22%

12 alerts

+19.22% Session close to close

+12.3% Peak in 6 hr 45 min

$4.94M Market Cap

1.2x Rel. Volume

In the Jun 30 session, FBLG gained 19.22%, reflecting a significant positive market reaction. Argus tracked a peak move of +12.3% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +19.2% in the session following this news. A strong positive reaction aligns with F...

Analysis

The stock surged +19.2% in the session following this news. A strong positive reaction aligns with FibroBiologics’ positioning as a clinical-stage cell therapy developer with 270+ patents. Recent financing and ATM capacity reduce near-term cash concerns, though additional equity raises could still pressure shares.

Key Figures

Intellectual property: 270+ patents issued and pending Conference edition: 4th Annual Conference dates: June 30 – July 1, 2026 +1 more

4 metrics

Intellectual property 270+ patents issued and pending Company patent portfolio referenced in conference announcement

Conference edition 4th Annual H.C. Wainwright Cell Therapy Virtual Conference

Conference dates June 30 – July 1, 2026 H.C. Wainwright Cell Therapy Virtual Conference schedule

Fireside chat time 1:00 p.m. ET on June 30, 2026 Scheduled FibroBiologics fireside chat slot

Historical Context

5 past events · Latest: Jun 26 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 26	Private placement	Negative	+12.7%	Dilutive private placement at $0.735 with additional warrant financing potential.
Jun 22	Patent allowance	Positive	+0.1%	USPTO Notice of Allowance for topical fibroblast spheroid wound-healing patent.
Jun 16	Clinical progress	Positive	-9.3%	Update on first patient dosing and additional GMP manufacturing for CYWC628 trial.
Jun 03	Clinical trial start	Positive	+1.9%	First patients dosed in Phase 1/2 CYWC628 trial for diabetic foot ulcers.
May 22	Preclinical data	Neutral	+0.0%	Preclinical psoriasis data for CYPS317 presented at dermatology conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

FBLG has shown mixed reactions, with some positive R&D and financing news met by both gains and declines.

Key Terms

clinical-stage, fibroblasts, fibroblast-derived materials, cell therapy

4 terms

clinical-stage medical

"FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

fibroblasts medical

"focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials"

Fibroblasts are common cells in connective tissue that manufacture the structural proteins and fibers—like collagen—that form and repair the body's scaffolding, helping wounds heal and tissues hold their shape. For investors, fibroblasts matter because they are frequent targets or tools in drug development, regenerative medicine and safety testing: changes in their behavior can signal whether a therapy will work, cause side effects or enable new medical products, much like a construction crew determines the strength and finish of a building.

fibroblast-derived materials medical

"potential cures for chronic diseases using fibroblasts and fibroblast-derived materials"

Materials produced or conditioned by fibroblasts—common connective‑tissue cells that secrete the structural proteins and other components tissues use as a scaffold. Investors should care because these biologically sourced materials are used in wound care, tissue engineering, cosmetic and regenerative products; their quality, scalability and regulatory path affect a product’s performance, manufacturing cost and commercial potential, much like the quality of bricks and mortar determines a building’s durability.

cell therapy medical

"H.C. Wainwright 4th Annual Cell Therapy Virtual Conference taking place June 30 – July 1, 2026"

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, June 30, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, and Chief Scientific Officer, Hamid Khoja, Ph.D., will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference taking place June 30 – July 1, 2026.

The fireside chat is scheduled for 1:00 p.m. ET on June 30, 2026, and will be moderated by Matthew Caufield, Senior Research Healthcare Analyst at H.C. Wainwright & Co. FibroBiologics will be available for one-on-one meetings throughout the event.

For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.  

About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-to-participate-in-fireside-chat-at-hc-wainwright-4th-annual-cell-therapy-virtual-conference-302813774.html

SOURCE FibroBiologics, Inc.

FAQ

What did FibroBiologics (Nasdaq:FBLG) announce for June 30, 2026?

FibroBiologics announced leadership participation in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. According to FibroBiologics, the event runs June 30–July 1, 2026 and includes one-on-one meeting availability.

When is FibroBiologics' fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference?

FibroBiologics' fireside chat is scheduled for 1:00 p.m. ET on June 30, 2026. According to FibroBiologics, this session is part of the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.

Who will represent FibroBiologics (FBLG) at the H.C. Wainwright Cell Therapy Conference?

FibroBiologics will be represented by Founder and CEO Pete O'Heeron and Chief Scientific Officer Hamid Khoja, Ph.D. According to FibroBiologics, they will participate in a moderated fireside chat during the virtual conference.

Will FibroBiologics (FBLG) hold one-on-one investor meetings at the 2026 H.C. Wainwright Cell Therapy Conference?

FibroBiologics plans to be available for one-on-one meetings throughout the virtual event. According to FibroBiologics, investors and other stakeholders can arrange meetings during the June 30–July 1, 2026 conference dates.

How can investors get more information about FibroBiologics' participation in the H.C. Wainwright Cell Therapy Conference?

Investors can visit FibroBiologics' website or email info@fibrobiologics.com for details. According to FibroBiologics, updates are also shared via its LinkedIn, YouTube, Facebook and X social media channels.